The United States and private plaintiffs challenged Tennessee SB1, which prohibits puberty blockers and hormone therapy for minors when used to treat gender dysphoria or help a minor live inconsistent with sex assigned at birth. The Supreme Court held that the law is not subject to heightened scrutiny under Equal Protection and survives rational-basis review.
Tennessee SB1 restricts certain medical treatments for minors when used for gender-transition purposes. The case came after families, medical providers, and the United States argued the law violated Equal Protection. The Court focused on whether heightened scrutiny applied and whether the law passed rational-basis review.
Does Tennessee SB1 violate the Equal Protection Clause by banning certain gender-affirming medical treatments for minors?
Tennessee's SB1 does not classify based on sex or transgender status for Equal Protection purposes and is subject to rational-basis review, which it satisfies.
How the justices lined up in this decision.
The ruling allows Tennessee's law to remain in effect and makes Equal Protection challenges to similar state bans harder. The people most directly affected are transgender minors, their parents, and clinicians. Families in states with similar bans may have to travel, delay care, or go without treatment that major U.S. medical associations have supported for some youth with gender dysphoria.
Chief Justice Roberts wrote the Court's opinion. Justices Thomas and Barrett filed concurrences; Justice Alito concurred in part and in the judgment. Justice Sotomayor dissented, joined by Justice Jackson and in large part by Justice Kagan; Justice Kagan also dissented separately.